Vertex Pharmaceuticals (NASDAQ: VRTX) recently announced positive results from an early stage clinical study of cell therapy VX-880 in treating type 1 diabetes. In this Motley Fool Live video recorded on Oct. 20, Fool.com contributors Keith Speights and Brian Orelli discuss the significance of this news for an experimental drug that has been referred to as a potential cure for type 1 diabetes. Vertex Pharmaceuticals announced encouraging results from a phase 1 study of its experimental cell therapy that has been touted to hold the potential to effectively cure type 1 diabetes in some patients.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting